- Home
- HI vs GERN Comparison
HI vs GERN Comparison
Compare HI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HI
- GERN
- Stock Information
- Founded
- HI 2007
- GERN 1990
- Country
- HI United States
- GERN United States
- Employees
- HI N/A
- GERN N/A
- Industry
- HI Miscellaneous manufacturing industries
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- HI Consumer Discretionary
- GERN Health Care
- Exchange
- HI Nasdaq
- GERN Nasdaq
- Market Cap
- HI 2.4B
- GERN 2.5B
- IPO Year
- HI N/A
- GERN 1996
- Fundamental
- Price
- HI $33.94
- GERN $2.89
- Analyst Decision
- HI Buy
- GERN Strong Buy
- Analyst Count
- HI 2
- GERN 10
- Target Price
- HI $36.50
- GERN $7.15
- AVG Volume (30 Days)
- HI 426.3K
- GERN 14.8M
- Earning Date
- HI 02-03-2025
- GERN 02-26-2025
- Dividend Yield
- HI 2.63%
- GERN N/A
- EPS Growth
- HI N/A
- GERN N/A
- EPS
- HI N/A
- GERN N/A
- Revenue
- HI $3,182,800,000.00
- GERN $29,480,000.00
- Revenue This Year
- HI N/A
- GERN $31,478.06
- Revenue Next Year
- HI $4.10
- GERN $290.89
- P/E Ratio
- HI N/A
- GERN N/A
- Revenue Growth
- HI 12.63
- GERN 9199.68
- 52 Week Low
- HI $25.11
- GERN $1.64
- 52 Week High
- HI $50.58
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- HI 67.20
- GERN 25.84
- Support Level
- HI $30.25
- GERN $2.80
- Resistance Level
- HI $31.79
- GERN $3.68
- Average True Range (ATR)
- HI 0.83
- GERN 0.18
- MACD
- HI 0.38
- GERN -0.04
- Stochastic Oscillator
- HI 91.38
- GERN 10.23
About HI Hillenbrand Inc
Hillenbrand Inc is a U.S.-based company that operates through two segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment. The Molding Technology Solutions segment offers engineered and customized systems in plastic technology and processing. It earns it revenue from Advanced Process Solutions, and Geographically from America, following by Asia and EMEA.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.